Pharma News

Novartis drug Afinitor extends progression-free survival in patients with advanced pancreatic neuroendocrine tumors

The New England Journal of Medicine (NEJM) published a study that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET)[1].

FDA Adds 13 Drugs to Watch List

The US Food and Drug Administration (FDA) has released its latest list of drugs to monitor based on potential signs of serious risks or new safety information identified in the agency's Adverse Event Reporting System (AERS).

The quarterly watch list consists of 13 medications that treat a wide range of conditions, including cough, angina, diabetes, cancer, and bipolar disorder.

Researchers from UTHealth & Athersys present data illustrating potential benefits of MultiStem for treating stroke

Medical researchers from The University of Texas Health Science Centre at Houston (UTHealth) presented new research results at the American Heart Association International Stroke Conference that demonstrated how MultiStem, a novel stem cell therapy being developed by Athersys, Inc. provided multiple benefits when administered in preclinical models of ischemic stroke.

National Cancer Institute begins phase II trial with Crolibulin in anaplastic thyroid cancer

EpiCept Corporation announced that the National Cancer Institute (NCI) has initiated a phase II trial with Crolibulin (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with Anaplastic Thyroid Cancer (ATC). Crolibulin is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumour activity in both preclinical and early clinical studies.

NIPER to organise 3-day symposium on DMPK in collaboration with Bristol Mayers Squibb

The National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, Punjab and Bristol Mayers Squibb are jointly organising an international symposium on ‘Drug Metabolism and Pharmacokinetics (DMPK)--Applications toward Drug Discovery and Development’ from February 11 to 13 at the NIPER premises.

Pages